These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 11091583)

  • 1. Meta-Analysis of the Second Collaborative Study of Adjuvant Chemoendocrine Therapy for Breast Cancer (ACETBC) in Patients with Stage II, Estrogen-Receptor-Positive Breast Cancer.
    Yoshida M; Abe O; Uchino J; Kikuchi K; Abe R; Enomoto K; Tominaga T; Fukami A; Sugimachi K; Nomura Y; Hattori T; Ogawa N
    Breast Cancer; 1997 Jul; 4(2):93-101. PubMed ID: 11091583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Postoperative adjuvant randomised trial comparing chemoendocrine therapy, chemotherapy and immunotherapy for patients with stage II breast cancer: 5-year results from the Nishinihon Cooperative Study Group of Adjuvant Chemoendocrine Therapy for Breast Cancer (ACETBC) of Japan.
    Morimoto T; Ogawa M; Orita K; Sugimachi K; Toge T; Dohi K; Nomura Y; Monden Y; Ogawa N
    Eur J Cancer; 1996 Feb; 32A(2):235-42. PubMed ID: 8664034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Role of Chemoendocrine Agents in Postoperative Adjuvant Therapy for Breast Cancer: Meta-analysis of the First Collaborative Studies of Postoperative Adjuvant Chemoendocrine Therapy for Breast Cancer (ACETBC).
    Abe O
    Breast Cancer; 1994 Jul; P(P):P-P9. PubMed ID: 11091512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Postoperative chemo-endocrine treatment with mitomycin C, tamoxifen, and UFT is effective for patients with premenopausal estrogen receptor-positive stage II breast cancer. Nishinihon Cooperative Study Group of Adjuvant Therapy for Breast Cancer.
    Sugimachi K; Maehara Y; Akazawa K; Nomura Y; Eida K; Ogawa M; Konaga E; Tanaka N; Toge T; Dohi K; Noda S; Maeda M; Monden Y
    Breast Cancer Res Treat; 1999 Jul; 56(2):113-24. PubMed ID: 10573104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct comparisons of adjuvant endocrine therapy, chemotherapy, and chemoendocrine therapy for operable breast cancer patients stratified by estrogen receptor and menopausal status.
    Nomura Y; Shirouzu M; Takayama T
    Breast Cancer Res Treat; 1998 May; 49(1):51-60. PubMed ID: 9694611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized trial of adjuvant endocrine therapy, chemotherapy, and chemoendocrine therapy for operable breast cancer stratified by estrogen receptors.
    Nomura Y; Tashiro H; Hisamatsu K; Shinozuka K
    Cancer; 1988 Jun; 61(11):2168-75. PubMed ID: 3130175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A comparative study among ftorafur, ftorafur plus tamoxifen, and tamoxifen in adjuvant therapy for breast cancer. The Chubu Cooperative Study Group of Adjuvant Chemoendocrine Therapy for Breast Cancer, Japan].
    Yoshida M; Saji S; Takagi H; Takeuchi S; Tsuda H; Nimura Y; Mizumoto R; Miyazaki I; Kobayashi S; Noguchi M
    Gan To Kagaku Ryoho; 1993 Dec; 20(15):2325-33. PubMed ID: 8259846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer.
    Fisher B; Jeong JH; Dignam J; Anderson S; Mamounas E; Wickerham DL; Wolmark N
    J Natl Cancer Inst Monogr; 2001; (30):62-6. PubMed ID: 11773294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. UFT and mitomycin plus tamoxifen for stage II, ER-positive breast cancer. Hokkaido ACETBC Study Group.
    Hata Y; Uchino J; Asaishi K; Kubo Y; Mito M; Tanabe T; Ogita M; Hirata K
    Oncology (Williston Park); 1999 Jul; 13(7 Suppl 3):91-5. PubMed ID: 10442372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of UFT plus Tamoxifen for Estrogen-Receptor-Positive Breast Cancer and Tamoxifen plus UFT for Estrogen-Receptor-Negative Breast Cancer : Adjuvant Therapy after Administration of Mitomycin.
    Ogita M; Uchino J; Asaishi K; Kubo Y; Tanabe T; Hata A; Hirata K; Mito M;
    Clin Drug Investig; 2003; 23(11):689-99. PubMed ID: 17536882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Positive effect of tamoxifen as part of adjuvant chemo-endocrine therapy for breast cancer. Hokkaido Adjuvant Chemo-Endocrine Therapy for Breast Cancer Study Group.
    Uchino J; Samejima N; Tanabe T; Hayasaka H; Mito M; Hata Y; Asaishi K
    Br J Cancer; 1994 Apr; 69(4):767-71. PubMed ID: 8142265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized adjuvant trial to evaluate the addition of tamoxifen and PSK to chemotherapy in patients with primary breast cancer. 5-Year results from the Nishi-Nippon Group of the Adjuvant Chemoendocrine Therapy for Breast Cancer Organization.
    Toi M; Hattori T; Akagi M; Inokuchi K; Orita K; Sugimachi K; Dohi K; Nomura Y; Monden Y; Hamada Y
    Cancer; 1992 Nov; 70(10):2475-83. PubMed ID: 1423177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of postoperative adjuvant therapy for stage ilia breast cancer: Futraful vs futraful+tamoxifen for ER-positive patients and futraful vs futraful + adriamycin for ER-negative breast cancer.
    Yoshida M; Abe O; Uchino J; Kikuchi K; Abe R; Enomoto K; Tominaga T; Fukami A; Sakai K; Koyama H; Sugimachi K; Nomura Y; Hattori T; Ogawa N
    Breast Cancer; 1997; 4(2):103-13. PubMed ID: 18843555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Post-operative Adjuvant Therapy for Stage IIIa Berast Cancer: Futraful vs Futraful+Tamoxifen for ER-positive Patients and Futraful vs Futraful+Adriamycin for ER-negative Breast Cancer.
    Yoshida M; Abe O; Uchino J; Kikuchi K; Abe R; Enomoto K; Tominaga T; Fukami A; Sakai K; Koyama H; Sugimachi K; Nomura Y; Hattori T; Ogawa N
    Breast Cancer; 1997 Jul; 4(2):103-113. PubMed ID: 11091584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of tamoxifen on breast recurrence, cosmesis, complications, and survival in estrogen receptor-positive early-stage breast cancer.
    Fowble B; Fein DA; Hanlon AL; Eisenberg BL; Hoffman JP; Sigurdson ER; Daly MB; Goldstein LJ
    Int J Radiat Oncol Biol Phys; 1996 Jul; 35(4):669-77. PubMed ID: 8690632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Appraisal of adjuvant chemoendocrine therapy with tamoxifen plus tegafur in patients with breast cancer.
    Enomoto K; Fujiwara K; Ikeda T; Katoh S; Abe O
    Keio J Med; 1991 Sep; 40(3):123-8. PubMed ID: 1753554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant setting].
    Inaji H; Sakai K; Oka T; Ozawa K; Saito Y; Senoo T; Taguchi T; Terasawa T; Nakao K; Mori T; Koyama H; Oshima A
    Gan To Kagaku Ryoho; 2006 Oct; 33(10):1423-9. PubMed ID: 17033231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized trial comparing ftorafur alone with ftorafur plus tamoxifen in postoperative adjuvant therapy for breast cancer. Kinki Area Research Group for Postoperative Adjuvant Therapy for Breast Cancer.
    Sakai K; Kosaki G; Seno T; Taguchi T; Terasawa T; Nakao K; Koyama H; Oshima A
    Cancer Chemother Pharmacol; 1996; 37(6):587-92. PubMed ID: 8612314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A cooperative randomized controlled study of adjuvant chemoendocrine therapy for breast cancer in Japan.
    Abe R; Tsuchiya A; Koie H; Ono K; Abo S; Saito K; Tsukamoto M; Sato T; Mori S; Kikuchi K
    Am J Clin Oncol; 1994 Apr; 17(2):103-8. PubMed ID: 8141101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.